Tevogen says PredicTcell training nears completion, precision improves about 10%

• Tevogen reported PredicTcell, machine-learning model for identifying immunologically active peptides, is nearing completion of its training phase.
• Model training used one of industry’s largest curated peptide datasets; feature expansion exceeded 180 parameters.
• Tevogen cited about 10% improvement in precision from latest feature expansion.
• Company began evaluating potential co-development partnerships to broaden use of platform aimed at improving target identification in drug development.
• Tevogen built initial internal application portal to serve PredicTcell in scalable environment, positioning platform for potential commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604271150PRIMZONEFULLFEED9707629) on April 27, 2026, and is solely responsible for the information contained therein.